Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow VALN
Valneva SE Sponsored ADR (VALN) Piotroski F-score
Valneva SE Sponsored ADR's Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | (2.00) |
| FY2024 | 4 | 2.00 |
| FY2023 | 2 | 2.00 |
| FY2022 | 0 | (5.00) |
| FY2021 | 5 | 1.00 |
| FY2020 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (26.27%) | (2.55%) | Fail | 0 |
| Positive operating cash flow | (59.84m) | (72.74m) | Fail | 0 |
| Rising return on assets | (26.27%) | (2.55%) | Fail | 0 |
| Cash flow above net income | 70.48m | (59.48m) | Pass | 1 |
| Falling long-term leverage | 0.37 | 0.35 | Fail | 0 |
| Rising current ratio | 2.38 | 2.61 | Fail | 0 |
| No new shares issued | 84,089,500 | 72,853,000 | Fail | 0 |
| Rising gross margin | 38.66% | 41.89% | Fail | 0 |
| Rising asset turnover | 0.40 | 0.35 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| PBYI Puma Biotechnology, Inc. compare | 8 |
| DBVT DBV Technologies S.A. compare | 4 |
| STTK Shattuck Labs, Inc. compare | 4 |
| SLN Silence Therapeutics PLC Sponsored ADR compare | 2 |
| VALN Valneva SE Sponsored ADR | 2 |
| VECT VectivBio Holding AG compare | — |
| SGMT Sagimet Biosciences Inc. compare | — |
| DRUG Bright Minds Biosciences Inc. compare | — |
| CRMD CorMedix Inc compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover